Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Leonora De Boo

Citation

Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240

Authors

L. De Boo1, A. Cimino-Mathews2, Y. Lubeck1, A. Daletzakis1, M. Opdam1, J. Sanders1, E. Hooijberg3, A.G.J. van Rossum1, Z. Loncova4, D. Rieder4, Z. Trajanoski5, M. Vollebergh6, M. Sobral-Leite1, K. Van de Vijver7, A. Broeks8, R. van der Wiel1, H. van Tinteren1, S.C. Linn6, H. Horlings1, M. Kok9

Author affiliations

  • 1 Molecular Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 2 Pathology And Oncology, The Johns Hopkins Hospital, Baltimore/US
  • 3 Pathology, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 4 Division Of Bioinformatics, Medical University of Innsbruck, innsbruck/AT
  • 5 Division Of Bioinformatics, Medical University of Innsbruck, 6020 - Innsbruck/AT
  • 6 Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 7 Department Of Pathology, Ghent University Hospital, 9000 - Gent/BE
  • 8 Department Of Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 9 Department Of Medical Oncology And Division Of Molecular Oncology & Immunolgy, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1006 BE - Amsterdam/NL
More

Resources

Abstract 3330

Background

The prognostic value of tumour-infiltrating lymphocytes (TILs) differs by breast cancer (BC) subtype. The aim of this study was to evaluate TILs in stage III BC in the context of BRCA1/2-like phenotypes and their association with outcome and benefit of intensified platinum-based chemotherapy.

Methods

Patients in this study participated in a randomized controlled trial of adjuvant intensified platinum-based chemotherapy versus conventional anthracycline-based chemotherapy carried out between 1993-1999 in stage III BC. Stromal TILs were scored according to International guidelines in these HER2-negative tumours. BRCA-profiles were determined using array-based Comparative Genomic Hybridization (aCGH) data.

Results

TIL levels were evaluated in 248 stage III breast tumours. High TILs are associated with TNBC. Tumours were classified as non-BRCA-like (n = 167), BRCA1-like (n = 30), BRCA2-like (n = 39) or BRCA1/2-like (n = 12). BRCA-like tumours harboured higher TILs compared to non-BRCA-like tumours (median TILs of 20% vs 10%, respectively, p < 0.01). TIL levels in BRCA1-like tumours were higher compared to BRCA2-like (median TILs of 20% vs 10%, respectively, p < 0.001) and non-BRCA-like tumours (median TILs of 10%, p < 0.001). These correlations remained significant within the ER-positive subgroup. Within TNBC, TIL levels were not higher in BRCA-like compared to non-BRCA-like tumours (median TILs of 30% vs 25%, respectively, p = 0.96). In this stage III BC cohort, high TIL level was associated with favourable outcome regarding recurrence-free and overall survival (TILs per 10% increment, HR 0.82, 95% CI 0.71-0.94, p = 0.01, respectively HR 0.80, 95% CI 0.68-0.94, p = 0.01). There was no significant interaction between TIL levels and benefit of intensified platinum-based chemotherapy.

Conclusions

In this high-risk breast cancer cohort, high TILs were associated with TNBC and BRCA1-like status. Within the ER-positive subgroup, TIL levels were higher in BRCA1-like compared to non-BRCA-like tumours, but this was not seen within the TNBC subgroup. When adjusted for clinical characteristics, TIL levels were significantly associated with a more favourable outcome in stage III BC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Dutch Cancer Society.

Disclosure

A. Cimino-Mathews: Research grant / Funding (self): BMS. S.C. Linn: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Cergentis; Advisory / Consultancy: Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Adienne; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Genentch; Research grant / Funding (institution): Tesaro. M. Kok: Advisory / Consultancy, Research grant / Funding (institution): BMS; Research grant / Funding (institution): Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings